-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Cinda Biologics Class 1 new drug IBI302 has obtained the implied approval of a clinical trial and plans to develop the treatment of diabetic macular edema (DME)
.
According to Cinda Bio's official information, IBI302 is a "first-in-class" drug under development independently developed by the company, and is the world's first bispecific fusion protein targeting vascular endothelial growth factor (VEGF) and complement
The clinical research indication approved by IBI302 this time is: diabetic macular edema
.
Public information shows that diabetic macular edema is one of the main causes of vision loss in adults